Andrey Meshcheryakov

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

Hans‐Joachim Schmoll, Eric Van Cutsem, Alexander Stein et al. · Annals of Oncology · 2012 · 1.5K citations · Full text

Medicine, Oncology, Surgery +17

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 389 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà et al. · Journal of Clinical Oncology · 2020 · 281 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma

Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank et al. · NEJM Evidence · 2022 · 150 citations

Pharmacy, Oncology, Pharmacotherapy +17

Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial

Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank et al. · European Journal of Cancer · 2024 · 81 citations · Full text

Medicine, Clinical Sciences, Oncology +14